


ORION-11

#ESCCongress



Trial Description: Patients with ASCVD or ASCVD risk-equivalents were randomized to inclisiran 300 mg injection administered on days 1, 90, 270, and 450 vs placebo.



RESULTS

- Primary endpoint: mean percent change in LDL-C at 510 days was -49 in the inclisiran group compared with 4 in the placebo group (p < 0.0001)

CONCLUSIONS

- Among patients with ASCVD or ASCVD risk-equivalents, twice yearly inclisiran injection resulted in a significant reduction in LDL-C

Presented by Dr. Kausik Ray at ESC Congress 2019